If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02715479","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"Treatment A","arm_group_description":"Single DTG tablet under fed conditions for a specified period","arm_type":"Experimental"},{"arm_group_label":"Treatment B","arm_group_description":"Two BMS955176 tablets under fed conditions for a specified period","arm_type":"Experimental"},{"arm_group_label":"Treatment C","arm_group_description":"Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period","arm_type":"Experimental"}],"assignment":"Single Group Assignment","brief_summary":"The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A study to evaluate the effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the pharmacokinetics of BMS-955176","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:42:06","criteria":"Inclusion Criteria: 1.Signed Informed Consent 2.Target population: Healthy males and females. 3. Women of child bearing potential (WOCBP) with negative serum pregnancy test 4. Women must not be breastfeeding 5.Men and WOCBP must agree to follow instructions for contraception Exclusion Criteria: 1.History of any chronic or acute illness, gastrointestinal disease, GI surgery, cardiac disease or clinically significant cardiac arrhythmia 2. History of frequent headaches or acute diarrhoea. 3. Any major surgery within 4 weeks of study drug administration 4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population 5. History of allergy to HIV maturation and integrase inhibitors,or related compounds 6. History of smoking","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"14","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"e3b829c2-dd5e-53a3-bcb7-a98323607db1","internal":{"content":null,"contentDigest":"f6a2a90c9de1bb94fb9b3806a6a1bf6b","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: 1.Signed Informed Consent 2.Target population: Healthy males and females. 3. Women of child bearing potential (WOCBP) with negative serum pregnancy test 4. Women must not be breastfeeding 5.Men and WOCBP must agree to follow instructions for contraception Exclusion Criteria: 1.History of any chronic or acute illness, gastrointestinal disease, GI surgery, cardiac disease or clinically significant cardiac arrhythmia 2. History of frequent headaches or acute diarrhoea. 3. Any major surgery within 4 weeks of study drug administration 4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population 5. History of allergy to HIV maturation and integrase inhibitors,or related compounds 6. History of smoking","interventions":[{"arm_group_label":"Treatment A","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir","intervention_type":"Drug"},{"arm_group_label":"Treatment C","intervention_description":"Dolutegravir","intervention_name":"Dolutegravir","intervention_type":"Drug"},{"arm_group_label":"Treatment B","intervention_description":"BMS955176","intervention_name":"BMS955176","intervention_type":"Drug"},{"arm_group_label":"Treatment C","intervention_description":"BMS955176","intervention_name":"BMS955176","intervention_type":"Drug"}],"interventional_subtype":"Other","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"05/01/2016 00:00:00","links":[{"description":"Description BMS Clinical Trial Education Resource","url":"http://www.bms.com/studyconnect/pages/home.aspx"},{"description":"Description BMS Clinical Trial Information","url":"http://ctr.bms.com/ctd/start.do"},{"description":"Description Investigator Inquiry Form","url":"http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx"},{"description":"Description FDA Safety Alerts and Recalls","url":"http://www.fda.gov/Safety/Recalls/"}],"locations":[{"City":"Austin","Latitude":"30.196311","CountryDisplay":"United States","Longitude":"-97.730807","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78744","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"50 years","maximum_age":"50","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:44:13","number_of_arms":"3","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Two-way Drug Interaction Study to Evaluate the Effect of BMS-955176 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176","org_study_id":"206222","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"05/01/2016 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Maximum observed plasma concentration (Cmax) for DTG","outcome_time_frame":"Days 1 to 5 and days 15 to 21","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve in 1 dosing interval AUC (tau) for DTG","outcome_time_frame":"Days 1 to 5 and days 15 to 21","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Maximum observed plasma concentration (Cmax) for BMS955176","outcome_time_frame":"Days 8-21","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the concentration-time curve in 1 dosing interval AUC (tau) for BMS955176","outcome_time_frame":"Days 8-21","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI468-052","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"The incidence of observed AEs will be tabulated and reviewed for potential significance and clinical importance.","outcome_measure":"Adverse events (AEs)","outcome_time_frame":"Days 1-21; for SAEs up to 30 days post discontinuation of dosing","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"04/01/2016 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206222"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}